

UPTAKE OF RADIOLABELED ESTRADIOL BY THE CANINE ADRENAL

Martin F. Sturman*, William H. Beierwaltes, Rodney D. Ice, and Suraj Prakash
University of Michigan Medical Center, Ann Arbor, Michigan

Tritiated estradiol injected intravenously into 11 mongrel dogs sacrificed at 3, 7, 10, 17, and 60 min showed maximum uptake in the adrenal gland at 3–7 min. The concentration of radioactivity in the adrenal in percent dose per gram equaled that from ¹³¹I-19-iodocholesterol. If a ¹³¹I-estradiol could be synthesized that would concentrate similarly in the adrenal, it would offer the advantage of almost instantaneous imaging after the tracer injection and a lower radiation dose.

Early studies with tritiated estradiol in the rat demonstrated two different types of tissue uptake patterns (1). In the "nonresponsive" tissue such as liver, kidney, muscle, blood, and adrenal, peak uptake occurred very early, within 10–15 min, with an extremely rapid decline. In the "growth responsive" tissues, uterus and vagina, these organs continued to incorporate and retain radioactivity for much longer, reaching a peak not before 1–2 hr without significant decline for another 1–5 hr.

Further reports confirm these findings in the female rat where highest concentrations of tritiated estrone and estradiol were found in adrenals after 3-hr infusions (2). Ullberg, et al (3) also had drawn attention to specific localization of radioactive estrone and estradiol in the adrenal cortex and ovaries of the rat. These findings were further confirmed for ¹⁴C-labeled mestranol, the cyclopentyl ether derivative of estradiol (4).

Because we have been interested and involved in

the development of adrenal scanning agents, most recently ¹³¹I-19-iodocholesterol (5–8), we hoped that if a tritiated estrogen concentrated sufficiently in the adrenal, a gamma-emitting analog might be synthesized for possible diagnostic use.

The studies reported here show that intravenous tritiated estradiol in the dog reaches the highest tissue concentration in the adrenal in 3–7 min and that this level exceeds that of all other tissues.

METHODS

Dogs. Eleven mongrel dogs, four females and seven males, 9–15 kg in weight, were injected intravenously and sacrificed at 3, 7, 10, 14, and 50 min as shown in Table 1. All dogs received 38–89 μ Ci ³H estradiol.

Radiolabeled steroids. Estradiol-2,4,6,7(n)-³H (85 and 100 Ci/mM) was obtained from Amersham/Searle, Chicago, Ill. Radiochemical purity 98% was documented by the suppliers by thin-layer silica gel, paper, and reverse-phase paper chromatography.

The radiosteroid as obtained was dissolved in benzene. The benzene was evaporated and the residue dissolved in absolute ethanol. Polysorbate 80 (1.0%) was added and sufficient normal saline to give a 20% ethanol solution having a specific concentration of 5–10 μ Ci/ml.

Received June 13, 1974; original accepted Aug. 14, 1974.

For reprints contact: William H. Beierwaltes, Section of Nuclear Medicine, University of Michigan, Ann Arbor, Mich. 48104.

* Present address: Nuclear Diagnostic Laboratories, 1401 Ocean Ave., Brooklyn, N.Y. 11230.

these sites were target areas of the estrogens. The greatest concentration was found in the adrenal cortex at 1 hr. The adrenal medulla showed no specific uptake. After 4 hr, a relatively increased activity was found at the sites of excretion, particularly the liver and intestine. By 24 hr the concentration in all the tissues except the excretory pathways was greatly reduced. After 4 days, no activity could be found in any tissues but the liver.

The peak uptake of radiolabeled estradiol observed by us in the adrenal of dogs at 3–7 min is remarkable in that the uptake in percent dose per gram equals the uptake we have previously observed with ¹³¹I-19-iodocholesterol in the dog (9) and in the human (5,7,8). If a ¹³¹I- or ¹¹C-labeled estradiol could be synthesized that would concentrate in the adrenal cortex of man in a concentration similar to the ³H-estradiol used here, it would allow almost instantaneous imaging of the adrenal after a tracer rather than the 3–14 days necessary with ¹³¹I-19-iodocholesterol (10). It would also offer the advantage of a shorter biologic half-life and lower radiation dose to the adrenal.

ACKNOWLEDGMENTS

This work was supported in part by USPHS Training Grant CA-05134-11 and 12, USAEC Grant AT (911-1) 2027, the Elsa U. Pardee Foundation, and the Nuclear Medicine Research Fund.

REFERENCES

1. JENSEN EV, JACOBSON HI: Basic guides to the mecha-

nism of estrogen action. *Recent Prog Horm Res* 18: 387, 1962

2. DE HERTOGH R, EKKA E, VANDERHEYDEN I: Equilibrium concentration of [6,7-³H] oestrone and [6,7-³H] 17β-oestradiol metabolites in female rat tissues during long-term intravenous infusions. *Acta Endocrinol* 66: 401–416, 1971

3. ULLBERG S, BENGTSSON G: Autoradiographic distribution studies with natural oestrogens. *Acta Endocrinol* 43: 75–86, 1963

4. APPELGREN LE, KARLSSON R: The distribution of labelled mestranol in mice. *Acta Endocrinol [Suppl]* 138: 84, 1969

5. BEIERWALTES WH, LIEBERMAN LM, ANSARI AN, et al: Visualization of human adrenal glands in vivo by scintillation scanning. *JAMA* 216: 275–277, 1971

6. COUNSELL RE, RANADE VV, BLAIR RJ, et al: Tumor localizing agents IX. Radioiodinated cholesterol. *Steroids*, 16: 317–328, 1970

7. LIEBERMAN LM, BEIERWALTES WH, CONN JW: Diagnosis of adrenal disease by visualization of human adrenal glands with ¹³¹I-19-iodocholesterol. *N Engl J Med* 285: 1387–1393, 1971

8. MORITA R, LIEBERMAN LM, BEIERWALTES WH, et al: Percent uptake of ¹³¹I radioactivity in the adrenal from radioiodinated cholesterol. *J Clin Endocrinol Metab* 34: 36–43, 1972

9. BLAIR RJ, BEIERWALTES WH, LIEBERMAN LM, et al: Radiolabeled cholesterol as an adrenal scanning agent. *J Nucl Med* 12: 176–182, 1971

10. BEIERWALTES WH, ANDERSON BG, MORITA R, et al: Some new isotopic procedures and techniques for endocrine diagnosis. In *Clinical Uses of Radionuclides: Critical Comparison with Other Techniques*, Symposium Series 27, Oak Ridge, Tenn, USAEC, 1972, pp 393–411

11. ANDERSON BH, BEIERWALTES WH: Adrenal imaging with radioiodocholesterol in the diagnosis of adrenal disorders. *Adv Intern Med* 19: 327–343, 1974

The Past, Present, and Future of Noninvasive Brain Imaging

January 19, 1975

Salt Lake City, Utah

**Hotel Utah
Lafayette Ballroom**

Sponsored by the Society of Nuclear Medicine

This program brings together experts to discuss and evaluate the strengths and weaknesses of currently used radionuclide techniques as well as the potential for developing new and improved radionuclide studies including the use of short-lived radionuclides, computer-assisted techniques, and three-dimensional imaging and the comparative clinical usefulness of radionuclide brain studies and computerized transmission reconstruction tomography. A panel discussion with audience participation will conclude the program. The panel will discuss the future of radionuclide brain studies, the impact of the new transmission techniques, and the proper clinical coordination of these two methods.

For more information contact:

Society of Nuclear Medicine
475 Park Avenue South
New York, N.Y. 10016